Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

infuzija - albumin

Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pekana naturheilmittel gmbh - ledum palustre; ruta graveolens spag. peka; arnica montana spag. peka; bryonia cretica spag. peka; guaiacum; toxicodendron quercifolium; viscum album spag. peka; bellis perennis spag. peka - krema - ledum palustre 4 d / 1 g  ruta graveolens spag. peka6 d / 1 g  arnica montana spag. peka12 d / 1 g  bryonia cretica spag. peka4 d / 1 g  guaiacum4 d / 1 g  toxicodendron quercifolium12 d / 1 g  viscum album spag. peka4 d / 1 g  bellis perennis spag. peka8 d / 1 g; ruta graveolens spag. peka 6 d / 1 g  arnica montana spag. peka12 d / 1 g  bryonia cretica spag. peka4 d / 1 g  guaiacum4 d / 1 g  toxicodendron quercifolium12 d / 1 g  viscum album spag. peka4 d / 1 g  bellis perennis spag. peka8 d / 1 g; arnica montana spag. peka 12 d / 1 g  bryonia cretica spag. peka4 d / 1 g  guaiacum4 d / 1 g  toxicodendron quercifolium12 d / 1 g  viscum album spag. peka4 d / 1 g  bellis perennis spag. peka8 d / 1 g; bryonia cretica spag. peka 4 d / 1 g  guaiacum4 d / 1 g  toxicodendron quercifolium12 d / 1 g  viscum album spag. peka4 d / 1 g  bellis perennis spag. peka8 d / 1 g; guaiacum 4 d / 1 g  toxicodendron quercifolium12 d / 1 g  viscum album spag. peka4 d / 1 g  bellis perennis spag. peka8 d / 1 g; toxicodendron quercifolium 12 d / 1 g  viscum album spag. peka4 d / 1 g  bellis perennis spag. peka8 d / 1 g; viscum album spag. peka 4 d / 1 g  bellis perennis spag. peka8 d / 1 g; bellis perennis spag. peka 8 d / 1 g - -

Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

raztopina za kožni vbodni test - alergijski testi

Európska únia - slovinčina - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Európska únia - slovinčina - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberkuloza, odporna proti multidrugom - antimikobakterij - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 in 5. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Európska únia - slovinčina - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemija, dlakasta celica - antineoplastična sredstva - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Európska únia - slovinčina - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - karcinom, pljučni pljuč - antineoplastična sredstva - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

adriapharm d.o.o. - kroglica - -

Európska únia - slovinčina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotiki za sistemsko uporabo - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Európska únia - slovinčina - EMA (European Medicines Agency)

medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginaza - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - spectrila je naveden kot sestavni del antineoplastic kombinirano zdravljenje za zdravljenje akutno limfoblastno levkemijo, (vse), pri pediatričnih bolnikih od rojstva do 18 let in odrasli.